5VB9
IL-17A in complex with peptide
5VB9 の概要
| エントリーDOI | 10.2210/pdb5vb9/pdb |
| 分子名称 | Interleukin-17A, Peptide inhibitor, 1,2-ETHANEDIOL, ... (5 entities in total) |
| 機能のキーワード | il17, inhibitor, immune system - inhibitor complex, immune system / inhibitor |
| 由来する生物種 | Homo sapiens (Human) 詳細 |
| 細胞内の位置 | Secreted: Q16552 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 31412.98 |
| 構造登録者 | Antonysamy, S.,Russell, M.,Zhang, A.,Groshong, C.,Manglicmot, D.,Lu, F.,Benach, J.,Wasserman, S.R.,Zhang, F.,Afshar, S.,Bina, H.,Broughton, H.,Chalmers, M.,Dodge, J.,Espada, A.,Jones, S.,Ting, J.P.,Woodman, M. (登録日: 2017-03-28, 公開日: 2018-02-14, 最終更新日: 2024-10-30) |
| 主引用文献 | Ting, J.P.,Tung, F.,Antonysamy, S.,Wasserman, S.,Jones, S.B.,Zhang, F.F.,Espada, A.,Broughton, H.,Chalmers, M.J.,Woodman, M.E.,Bina, H.A.,Dodge, J.A.,Benach, J.,Zhang, A.,Groshong, C.,Manglicmot, D.,Russell, M.,Afshar, S. Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery. PLoS ONE, 13:e0190850-e0190850, 2018 Cited by PubMed Abstract: To date, IL-17A antibodies remain the only therapeutic approach to correct the abnormal activation of the IL-17A/IL-17R signaling complex. Why is it that despite the remarkable success of IL-17 antibodies, there is no small molecule antagonist of IL-17A in the clinic? Here we offer a unique approach to address this question. In order to understand the interaction of IL-17A with its receptor, we combined peptide discovery using phage display with HDX, crystallography, and functional assays to map and characterize hot regions that contribute to most of the energetics of the IL-17A/IL-17R interaction. These functional maps are proposed to serve as a guide to aid in the development of small molecules that bind to IL-17A and block its interaction with IL-17RA. PubMed: 29329326DOI: 10.1371/journal.pone.0190850 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.7 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






